Imagine if doctors could tell if a cancer drug is working within days instead of waiting months to see if a tumor shrinks. This technology acts like a high-definition metabolic camera that spots whether cancer cells are actually dying in real-time. It stops patients from wasting time on treatments that don't work and prevents them from suffering unnecessary side effects.
Clinicians currently rely on a trial-and-error approach to cancer treatment, waiting 3-4 months to see if a tumor shrinks. This leads to patients suffering side effects from ineffective drugs and wastes expensive medical resources.
A Hyperpolarized Magnetic Resonance (HypMR) imaging system and associated contrast agents to detect treatment response in days.
If you are a hardware producer dealing with the need for higher diagnostic precision — this project developed Hyperpolarized Magnetic Resonance (HypMR) imaging that allows radiologists to see tissue metabolism in real-time. This enables the commercialization of clinical polarizers and consumables.
If you are a drug developer dealing with low success rates in expensive immunotherapies, which can cost more than €100,000 per patient — this project developed a way to track drug effects in real-time. This allows for faster validation of treatment efficacy during clinical trials.
If you are a clinic dealing with the trial-and-error approach of chemotherapy where results take 3-4 months to confirm — this project developed a molecular imaging modality that detects non-responders after the first treatments. This improves patient outcomes and reduces wasted resources.
Commercialization of the clinical polarizer and consumables, including the contrast agent, is expected to generate cumulative revenues of more than 250M€ within 5 years post-market entry.
Yes, while breast cancer is the first use case, the technology is designed to characterize prostate cancer, other cancers, cardiometabolic diseases, and neurodegenerative diseases.
Based on available project data, the project involves a consortium of 6 partners including the SME Polarize, which is positioned to use the R&D for commercialization and raising capital.
It targets the reduction of spending on non-effective treatments, such as immunotherapies that can cost over €100,000 per patient with only 15-20% success rates.
The project runs from June 2024 to September 2027, focusing on R&D towards multicenter clinical studies and market entry.
The consortium is heavily academic, with 5 universities and only 1 SME (Polarize), resulting in an industry ratio of 17%. This structure suggests the project is in a transition phase where high-level research from Denmark, Germany, and Israel is being funneled into a single commercial vehicle (the SME) to prepare for capital investment and clinical trials.
Contact Aarhus Universitet regarding the RESPONSE project coordination.
Contact us to connect with the SME Polarize for early licensing opportunities.
